ストックスクリーナーアプリを入手
22.35
0.72%
0.16
プレマーケット:
22.84
0.49
+2.19%
Acadia Pharmaceuticals Inc (ACAD) 最新ニュース
Acadia Pharmaceuticals officer Kihara sells $29,024 stock - Investing.com
Acadia Pharmaceuticals CFO Mark Schneyer sells $76,395 in stock - Investing.com
ACADIA PHARMACEUTICALS (NASDAQ: ACAD) officer sells shares for RSU tax withholding - Stock Titan
Acadia Pharmaceuticals (ACAD) CFO sells shares to cover RSU taxes - Stock Titan
FDA Approval for NUPLAZID issued to ACADIA PHARMS INC - Quantisnow
MSN Money - MSN
ACADIA Pharmaceuticals (ACAD) Q1 2026 Preview: EPS Est. $0.08, Reports May 6 - AlphaStreet
Acadia Pharmaceuticals appoints Jonathan M. Poole to board of directors - Investing.com
Acadia R&D Chief Plans Retirement As Company Stresses Pipeline Continuity - Sahm
BofA Securities Upgrades ACADIA Pharmaceuticals to Buy Rating - HarianBasis.co
ACADIA (ACAD) Upgraded to Buy After Recent Pullback - Insider Monkey
ACADIA Pharmaceuticals | 8-K: Current report - Moomoo
Acadia Pharmaceuticals Announces Retirement of Head of Research & Development, Ensures Continuity for Alzheimer’s and Lewy Body Dementia Clinical Trials - Minichart
Acadia Announces Planned Retirement of Head of R&D - TipRanks
Acadia Pharmaceuticals (ACAD) Tops Q1 Earnings and Revenue Estimates (Revised) - MSN
Acadia Pharmaceuticals Announces Planned Year-End Retirement of Elizabeth H.Z. Thompson, Ph.D., Head of Research and Development, Following a Distinguished Career - BioSpace
Acadia Pharmaceuticals (NASDAQ: ACAD) details R&D head’s planned retirement and transition - Stock Titan
Pictet Asset Management Holding SA Buys 84,055 Shares of ACADIA Pharmaceuticals Inc. $ACAD - MarketBeat
Acadia Pharmaceuticals (ACAD) Expected to Beat Earnings Estimates: Should You Buy? - Yahoo Finance
ACADIA Pharmaceuticals (ACAD) to Release Earnings on Wednesday - MarketBeat
Acadia Pharmaceuticals to Participate at Upcoming May 2026 Investor Conferences - BioSpace
Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences - Yahoo Finance
ACADIA Pharmaceuticals | SCHEDULE 13G: Others - Moomoo
Vanguard files Schedule 13G: ACAD (NASDAQ: ACAD) 8.78M shares, 5.15% - Stock Titan
ACAD Stock Price, Quote & Chart | ACADIA PHARMACEUTICALS INC (NASDAQ:ACAD) - ChartMill
Acadia Pharmaceuticals to Participate in the Stifel 2026 Virtual CNS Forum - Business Wire
Here's why Acadia Pharmaceuticals (ACAD) is a strong momentum stock - MSN
Here's Why Acadia Pharmaceuticals (ACAD) is a Strong Momentum Stock - MSN
Axecap Investments LLC Has $3.65 Million Stock Holdings in ACADIA Pharmaceuticals Inc. $ACAD - MarketBeat
ACADIA PHARMACEUTICALS INC ($ACAD) CEO 2025 Pay Revealed - Quiver Quantitative
ACADIA Pharmaceuticals | DEF 14A: Definitive information statements - Moomoo
ACADIA Pharmaceuticals Inc. (ACAD) PT Trimmed Slightly as RBC Flags Seasonal Biotech Headwinds - Insider Monkey
Acadia (NASDAQ: ACAD) plans 2026 virtual meeting, equity incentive share increase - Stock Titan
Acadia (ACAD) Stock: Is It Overpriced in Market | Q4 2025: Better Than ExpectedHot Market Picks - Cổng thông tin điện tử Tỉnh Sơn La
5 Most Undervalued Healthcare Stocks to Buy Now - Insider Monkey
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
(ACAD) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Assessing Acadia Pharmaceuticals (ACAD) Valuation After DAYBUE STIX Rollout And Upcoming Neurology Data Presentations - Sahm
Acadia Pharmaceuticals to Present Data at the 2026 American Academy of Neurology (AAN) Annual Meeting - The National Law Review
BofA Securities Maintains ACADIA Pharmaceuticals(ACAD.US) With Buy Rating, Maintains Target Price $29 - Moomoo
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Short Interest Update - MarketBeat
Acadia Pharmaceuticals to Announce First Quarter 2026 Financial Results on May 6, 2026 - BioSpace
Acadia Pharmaceuticals to Report Q1 2026 Earnings on May 6 - National Today
How Investors Are Reacting To ACADIA Pharmaceuticals (ACAD) Expanding DAYBUE STIX Access for Rett Syndrome - Yahoo Finance
Press Release: Acadia Pharmaceuticals to Announce First Quarter 2026 Financial Results on May 6, 2026 - Moomoo
ACADIA Pharmaceuticals stock (US0042251084): Is the next product pipeline now the real test for sust - AD HOC NEWS
Acadia launches powder version of Rett syndrome treatment in the US - MSN
ACADIA Pharmaceuticals Announces Advancement by Allergan of Novel Glaucoma Compound into Preclinical - Yahoo
0.14%
0.48%
大文字化:
|
ボリューム (24 時間):